From Main Venue Presentations to Strategic Partnering, Taiwan’s Biotech Sector Makes Its Mark in JPM 2026

The 44^th Annual J.P. Morgan Healthcare Conference (JPM 2026) officially kicked off in San Francisco on January 12. As the world’s premier healthcare investment symposium, the conference gathers global industry leaders, policymakers, and top-tier investors. With billion-dollar deals often announced during the event, it is widely regarded as the industry’s “bellwether,” setting the tone for investment trends and development for the year ahead.

According to official figures, this year’s 4-day event is expected to attract over 8,000 attendees, including more than 3,000 CEOs and senior executives from biopharma companies. Taiwan, an emerging player in the Asia-Pacific biomedical landscape, is well-represented. From exclusive presentations at the main venue to active participation in satellite events and business partnering sessions, Taiwanese companies are showcasing their commercial capabilities and technical value to the international capital market, actively seeking cross-border licensing and funding opportunities.

Bora and PharmaEssentia to Unveil Strategic Roadmaps

Amid the extensive agenda of JPM 2026, only invited top-tier companies secure a spot to present at the main venue within The Westin St. Francis. An invitation to the “Main Track” signifies a company’s scale and visibility to global institutional investors. A highlight for Taiwan this year is the inclusion of two leading companies, Bora Pharmaceuticals and PharmaEssentia, which will deliver back-to-back presentations on the final day of the conference (January 15).

Bora Pharmaceuticals, with Chairman and CEO Bobby Sheng as the presenter, will make its first appearance on the main venue to engage with global investors following major U.S. acquisitions including Upsher-Smith and Pyros, and its entry into the U.S. capital market through the issuance of Level 1 American Depositary Receipts (ADRs). The market anticipates that Sheng will provide a deep dive into the company’s “Dual Engine Strategy”—synergizing CDMO services with Global drug sales. He will outline Bora’s plans for leveraging supply chain synergies from recent cross-border M&A to accelerate expansion in the U.S. market.

PharmaEssentia will feature a presentation by founder and CEO Dr. Ko-Chung Lin. Dr. Lin will update investors on the strong sales momentum of BESREMi (Ropeginterferon alfa-2b) for polycythemia vera (PV). Crucially, he is likely to share the company’s expansion strategy for 2026, which includes the NDA submission for a second indication, essential thrombocythemia (ET), and the launch of a patient-centric “pre-filled syringe.” These initiatives aim to further consolidate PharmaEssentia’s global competitive edge in the treatment of myeloproliferative neoplasms (MPN).

Targeting Innovation: Tech Players Active in Satellite Events

Beyond the headline presentations at the main venue, satellite events running concurrently, including the Biotech Showcase, RESI, and BFC Conference, serve as critical battlegrounds for emerging companies to secure licensing deals and early-stage investment. For JPM 2026, several Taiwanese firms armed with innovative technologies are taking a proactive approach to demonstrate their R&D capabilities.

HanchorBio, a company specializing in oncology and autoimmune diseases with its proprietary “Fc-based Biologics Discovery Platform” (FBDB), is actively participating in this year’s JPM week activities. The company’s newly appointed President Dr. Alvin Luk and Chief Business Officer Dr. Yuehua Cong are in San Francisco to engage with partners and investors, seeking potential cross-border tech licensing deals and business development opportunities.

Similarly focused on international connectivity is TaiMed Biologics. CEO Dr. Jimmy Chang indicated earlier this month that the company has arranged meetings with multiple licensing consultancies during JPM 2026. External attention is focused on updates regarding the clinical development of its long-acting HIV regimen, TMB-365/TMB-380, and plans to leverage business partnering at the conference to expand international orders for its high-barrier biologics CDMO business. 

Three Key Trends Defining JPM 2026: AI, M&A, and Obesity

Back to the theme of this year’s conference, industry analyses and publicly available information from JPM2026’s official website suggest a shift in market sentiment. Investors are no longer satisfied with “conceptual” tech breakthroughs, instead focusing on “tangible applications” and “commercial returns.” Among various hot topics, three pivotal trends are particularly likely to dominate discussions in 2026:

1. AI in Action: Investors are moving beyond the hype of AI platforms to scrutinize practical applications. The key questions now are: “Which candidate drugs has AI actually identified?” and “How much has Generative AI tangibly reduced clinical R&D costs?” In addition, legal and regulatory compliance, cybersecurity and privacy, as well as ethical issues arising from AI applications in the life sciences sector are also expected to draw significant attention at the conference.

2. M&A Resurgence: With global pharma giants facing an imminent “Patent Cliff” and interest rates stabilizing, 2026 is predicted to be a strong year for M&A. Cash-rich Big Pharmas will actively acquire small and medium-sized biotech companies with cutting-edge technologies to bridge revenue gaps, with oncology and immunology being the hottest sectors.

3. The Obesity Supply Chain: The craze for GLP-1 weight-loss drugs continues, but the competitive focus has shifted from efficacy data to supply stability and oral formulations. Investors are closely watching the scalability of the related supply chain, including CDMOs and API manufacturers, as well as breakthroughs in oral drug bioavailability.

Overall, JPM 2026 is not only the annual flagship event for the biotech capital markets, but also as a touchstone for the international competitiveness of Taiwan’s biotech sector. GeneOnline will continue to provide in-depth coverage throughout the event, bringing readers the latest updates on Taiwan’s major biopharma companies and global strategic trends.

Author

Richard Chau